CA2959670C - Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm - Google Patents

Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm Download PDF

Info

Publication number
CA2959670C
CA2959670C CA2959670A CA2959670A CA2959670C CA 2959670 C CA2959670 C CA 2959670C CA 2959670 A CA2959670 A CA 2959670A CA 2959670 A CA2959670 A CA 2959670A CA 2959670 C CA2959670 C CA 2959670C
Authority
CA
Canada
Prior art keywords
nen
expression level
gep
biomarkers
test sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2959670A
Other languages
English (en)
French (fr)
Other versions
CA2959670A1 (en
Inventor
Irvin Mark MODLIN
Mark Kidd
Ignat Drozdov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clifton Life Sciences LLC
Original Assignee
Clifton Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clifton Life Sciences LLC filed Critical Clifton Life Sciences LLC
Publication of CA2959670A1 publication Critical patent/CA2959670A1/en
Application granted granted Critical
Publication of CA2959670C publication Critical patent/CA2959670C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2959670A 2014-09-15 2015-09-15 Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm Active CA2959670C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462050465P 2014-09-15 2014-09-15
US62/050,465 2014-09-15
PCT/US2015/050274 WO2016044330A1 (en) 2014-09-15 2015-09-15 Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm

Publications (2)

Publication Number Publication Date
CA2959670A1 CA2959670A1 (en) 2016-03-24
CA2959670C true CA2959670C (en) 2024-02-20

Family

ID=54207775

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2959670A Active CA2959670C (en) 2014-09-15 2015-09-15 Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm

Country Status (13)

Country Link
US (4) US10407730B2 (https=)
EP (2) EP3194618B1 (https=)
JP (2) JP6782700B2 (https=)
KR (2) KR102762958B1 (https=)
CN (1) CN107208132A (https=)
AU (3) AU2015317893B2 (https=)
CA (1) CA2959670C (https=)
DK (2) DK3929303T3 (https=)
ES (2) ES2881474T3 (https=)
IL (2) IL250867B (https=)
MX (2) MX386919B (https=)
PL (2) PL3929303T3 (https=)
WO (1) WO2016044330A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3194618B1 (en) 2014-09-15 2021-04-21 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
KR102763004B1 (ko) * 2017-05-25 2025-02-04 리퀴드 바이옵시 리서치 엘엘씨 흑색종의 검출 방법
KR20250123230A (ko) * 2017-11-30 2025-08-14 리퀴드 바이옵시 리서치 엘엘씨 유전자 발현 검정을 이용한 펩티드 수용체 방사선요법의 예측
CN108048564B (zh) * 2018-02-09 2021-03-05 中国科学院昆明动物研究所 人glt8d1基因的新用途
WO2020027732A1 (en) * 2018-07-30 2020-02-06 Agency For Science, Technology And Research Method and system for assessing fibrosis in a tissue sample
MX2022004372A (es) 2019-10-10 2022-07-27 Liquid Biopsy Res Llc Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn.
FR3110764B1 (fr) * 2020-05-20 2024-05-10 Quantum Surgical Méthode de prédiction de la récidive d’une lésion par analyse d’images
CN113215255B (zh) * 2021-04-26 2022-04-05 山东天川精准医疗科技有限公司 用于肝癌早期诊断或预后的生物标记物及其用途
US20260021141A1 (en) * 2022-07-15 2026-01-22 Emendobio Inc. Strategies For Knock-Ins At APLP2 Safe Harbor Sites
KR20250080875A (ko) * 2022-09-30 2025-06-05 리퀴드 바이옵시 리서치 엘엘씨 타액에서 신경내분비암을 검출하는 방법
CN117292755B (zh) * 2023-08-09 2026-02-06 郑州大学 多模态临界边生物标志物识别方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020795A2 (en) 2003-08-25 2005-03-10 The Johns Hopkins University Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differntial gene expression analysis
CA2727082C (en) * 2008-06-12 2019-02-26 Syntaxin Limited Fusion proteins for use in suppression of acromegaly
WO2012119013A1 (en) * 2011-03-01 2012-09-07 Yale University PREDICTING GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NENs)
EP3194618B1 (en) 2014-09-15 2021-04-21 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm

Also Published As

Publication number Publication date
MX2021012347A (es) 2021-10-22
IL281355B (en) 2022-02-01
ES3013599T3 (en) 2025-04-14
DK3929303T3 (da) 2025-03-03
AU2021212151A1 (en) 2021-08-26
KR102762958B1 (ko) 2025-02-04
IL250867B (en) 2021-03-25
US11168372B2 (en) 2021-11-09
US20160076106A1 (en) 2016-03-17
IL281355A (en) 2021-04-29
CN107208132A (zh) 2017-09-26
IL250867A0 (en) 2017-04-30
JP7157788B2 (ja) 2022-10-20
JP6782700B2 (ja) 2020-11-11
US20220325351A1 (en) 2022-10-13
EP3929303B1 (en) 2024-12-04
EP3194618A1 (en) 2017-07-26
WO2016044330A1 (en) 2016-03-24
JP2021019618A (ja) 2021-02-18
EP3929303A1 (en) 2021-12-29
AU2021212151B2 (en) 2023-08-03
EP3194618B1 (en) 2021-04-21
PL3194618T3 (pl) 2021-12-13
US10407730B2 (en) 2019-09-10
MX386919B (es) 2025-03-19
US20260043085A1 (en) 2026-02-12
KR20170045365A (ko) 2017-04-26
US20190345568A1 (en) 2019-11-14
JP2017528164A (ja) 2017-09-28
ES2881474T3 (es) 2021-11-29
AU2015317893B2 (en) 2021-05-20
AU2023258444A1 (en) 2023-11-23
BR112017005279A2 (pt) 2017-12-12
CA2959670A1 (en) 2016-03-24
KR20250021631A (ko) 2025-02-13
US12258633B2 (en) 2025-03-25
PL3929303T3 (pl) 2025-04-28
AU2015317893A1 (en) 2017-03-23
MX2017003370A (es) 2017-11-22
DK3194618T3 (da) 2021-07-12

Similar Documents

Publication Publication Date Title
CA2959670C (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
US11746380B2 (en) Classification and prognosis of cancer
US9988684B2 (en) Predicting gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)
JP2020150949A (ja) メラノーマ癌の予後予測
US20210233611A1 (en) Classification and prognosis of prostate cancer
EP1977237A1 (en) Prognosis prediction for colorectal cancer
JP2024519082A (ja) 肝細胞がんのdnaメチル化バイオマーカー
HK40066027A (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
HK40066027B (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
HK1241416B (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
BR112017005279B1 (pt) Métodos para detectar um neoplasma neuroendócrino gastroenteropancreático (gep-nen), para diferenciar gep-nen estável de um gep-nen progressivo e para determinar uma resposta a uma terapia com radionucleotídeo para receptor de peptídeo de um gep-nen

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200911

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240912

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240912

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240912

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250901

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250909